Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PER2 | O15055 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.43 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30336667 | 0.81 | LMNA (0.57) | PER2KMT2AMEN1TDP1MAPT | |
| SCHEMBL23997291 | 0.81 | LMNA (0.57) | PER2KMT2AMEN1TDP1MAPT | |
| SCHEMBL30406343 | 0.80 | SMN1; SMN2 (0.57) | KMT2AMEN1POLBMAPTTSHR | |
| SCHEMBL14047589 | 0.74 | TDP1 (0.54) | PER2KMT2AMEN1POLBTDP1 | |
| SCHEMBL16865695 | 0.73 | MEN1 (0.50) | KMT2AMEN1POLBTDP1MAPT | |
| SCHEMBL5948078 | 0.72 | TDP1 (0.53) | PER2KMT2AMEN1POLBTDP1 | |
| SCHEMBL17195415 | 0.70 | LMNA (0.47) | PER2KMT2AMEN1POLBMAPT | |
| SCHEMBL6200777 | 0.69 | SIGMAR1 (0.71) | KMT2AMEN1POLBTSHRSIGMAR1 | |
| SCHEMBL23997227 | 0.69 | PER2 (0.40) | PER2TSHR | |
| SCHEMBL102338 | 0.69 | SIGMAR1 (0.71) | KMT2AMEN1POLBTSHRSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | HOFFMANN LA ROCHE INC. (US) | 2020-06-16 | — | — | US | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| EP-3484886-B1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN LA ROCHE (CH) | 2020-03-04 | — | — | EP | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | HOFFMANN-LA ROCHE INC. (US) | 2019-08-15 | — | — | US | disclosed |
| EP-3484886-A1 | 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | Hoffmann-La Roche AG (CH) | 2019-05-22 | — | — | EP | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | NANT HOLDINGS IP, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC | 2015-10-22 | — | — | US | disclosed |
| EP-2914253-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | Nant Holdings IP, LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| WO-2014071298-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | NANT HOLDINGS IP, LLC (US) | 2014-05-08 | — | — | WO | disclosed |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-02 | — | — | US | disclosed |
| EP-1723164-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005095440-A1 | BETA-AMINOACID-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-13 | — | — | WO | disclosed |
| EP-1571154-A1 | Beta-aminoacid-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190248792-A1 | NOVEL PYRAZOLOPYRAZINE AND TRIAZOLOPYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES | CYP3A5, RRP15, HAVCR2 | PER2 2257/4885KMT2A 3884/4885MEN1 2751/4885 |
| US-10183013-B2 | Cyclic sulfonamide containing derivatives as inhibitors of hedgehog signaling pathway | SMO, SHH, SOS1 | PER2 466/4885KMT2A 2126/4885MEN1 2551/4885 |
| US-10683299-B2 | Pyrazolopyrazine and triazolopyrazine compounds for the treatment of infectious diseases | CYP3A5, RRP15, QDPR | PER2 2071/4885KMT2A 3672/4885MEN1 2343/4885 |
| US-20150299190-A1 | CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY | SMO, SHH, SOS1 | PER2 466/4885KMT2A 2126/4885MEN1 2551/4885 |
| US-20070179122-A1 | Beta-Aminoacid-Derivatives As Factor Xa Inhibitors | F12, F11, F5 | PER2 4029/4885KMT2A 1442/4885MEN1 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.